WWW.THESIS.XLIBX.INFO
FREE ELECTRONIC LIBRARY - Thesis, documentation, books
 
<< HOME
CONTACTS



Pages:     | 1 |   ...   | 50 | 51 || 53 | 54 |   ...   | 181 |

«PacifiCare’s medical management guidelines represent the recommendation of the PacifiCare Medical Management Guideline (MMG) committee. They are ...»

-- [ Page 52 ] --

Autism Spectrum Disorder: Chelation therapy has been proposed to treat patients with autism based on the theory that the chelating agent will remove mercury from children with autism. Some studies have evaluated the use of chelation for treating autism (Patel, 2007); however, no studies have proven the effectiveness of chelation for this indication. In 2008, the National Institute of Mental Health called off a study on chelation to treat autism in children. The study was put on hold due to safety concerns after another study linked a drug used in the treatment to brain problems in rats. Scientists had planned to test a chelation drug on autistic children to investigate whether mercury in childhood vaccines causes the disorder. (Smart Brief, 2008) Professional Societies American Cancer Society (ACS): In 2007, the ACC stated that chelation therapy is a proven treatment for lead poisoning and poisoning from other heavy metals. However, available scientific evidence does not support claims that the treatment benefits patients with cancer, heart disease, or any medical problems other than heavy-metal poisoning.

(ACS, 2007) American College of Cardiology (ACC): The ACC concluded in 2005 that there is insufficient scientific evidence to justify the application of chelation therapy for atherosclerosis on a clinical basis. At the present time, therefore, chelation therapy should be applied only under an investigational protocol. (Vogel, 2005) American Heart Association (AHA): The AHA's Clinical Science Committee has reviewed the available literature on the use of chelation (EDTA) in the treatment of arteriosclerotic heart or blood vessel disease and finds no scientific evidence to demonstrate any benefit of this form of therapy. Furthermore, employment of this form of unproven treatment may deprive patients of the well-established benefits attendant to the many other valuable methods of treating these diseases. (AHA, 2009) American College of Physicians (ACP): A clinical practice guideline published in 2004 by the ACP recommended against the use of chelation therapy to prevent myocardial infarction or to reduce symptomatic angina. (Snow, 2004) Additional Medical Products Pencillamine or Depen® Additional Search Terms 1,2-dimethyl-3-hydroxypyrid-4-one, CGP 37 391, CP20, cupriuresis, DFX, DMHP, INN, lead encephalopathy, N,N'-bis (o-hydroxybenzyl) ethylenediamine-N, N'-diacetic acid, plumbism Chelation Therapy - Commercial Medical Management Guideline References and Resources Resources Addis A, Loebstein R, Koren G, Einarson TR. Meta-analytic review of the clinical effectiveness of oral deferiprone (L1).

Eur J Clin Pharmacol. 1999;55(1):1-6.

American Academy of Pediatrics (AAP). Aluminum toxicity in infants and children. Pediatrics. 1996;97(3):413-416.

American Academy of Pediatrics (AAP) Committee on Environmental Health. Lead exposure in children: prevention, detection, and management. Pediatrics. 2005 Oct;116(4):1036-46.

American Cancer Society (ACS). Chelation Therapy. July 20, 2007. Available at:

http://www.cancer.org/docroot/ETO/content/ETO_5_3x_Chelation_Therapy.asp. Accessed March 13, 2009.

American Heart Association (AHA) [Web site]. Questions and Answers About Chelation Therapy. 2009. Available at:

http://www.americanheart.org/presenter.jhtml?identifier=3000843. Accessed March 13, 2009.

Anderson TJ, Hubacek J, Wyse DG, et al. Effect of chelation therapy on endothelial function in patients with coronary artery disease: PATCH substudy. J Am Coll Cardiol. 2003;41(3):420-425.

Barata JD, D'Haese PC, Pires C, et al. Low-dose (5 mg/kg) desferrioxamine treatment in acutely aluminum-intoxicated haemodialysis patients using two drug administration schedules. Nephrol Dial Transplant. 1996;11(1):125-132.

Bellinger DC, Trachtenberg F, Barregard L, Tavares M, Cernichiari E, Daniel D, McKinlay S. Neuropsychological and renal effects of dental amalgam in children: a randomized clinical trial. JAMA. 2006 Apr 19;295(15):1775-83.

Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood. 2006 May 1;107(9):3455-62.

Caro J, Huybrechts KF, Green TC. Estimates of the effect on hepatic iron of oral deferiprone compared with subcutaneous desferrioxamine for treatment of iron overload in thalassemia major: a systematic review. BMC Blood Disord. 2002;2(1):4. Available at: http://www.biomedcentral.com/1471-2326/2/4. Accessed February 24, 2009.

Chisolm JJ Jr. Safety and efficacy of meso-2,3-dimercaptosuccinic acid (DMSA) in children with elevated blood lead concentrations. J Toxicol Clin Toxicol. 2000;38(4):365-375.

Crapper McLachlan DR, Dalton AJ, Kruck TP, et al. Intramuscular desferrioxamine in patients with Alzheimer's disease.

Lancet. 1991;337(8753):1304-1308.

DeRouen TA, Martin MD, Leroux BG, Townes BD, Woods JS, Leitao J, Castro-Caldas A, Luis H, Bernardo M, Rosenbaum G, Martins IP. Neurobehavioral effects of dental amalgam in children: a randomized clinical trial. JAMA.

2006 Apr 19;295(15):1784-92.

Dietrich KN, Ware JH, Salganik M, Radcliffe J, Rogan WJ, Rhoads GG, Fay ME, Davoli CT, Denckla MB, Bornschein RL, Schwarz D, Dockery DW, Adubato S, Jones RL; Treatment of Lead-Exposed Children Clinical Trial Group. Effect of chelation therapy on the neuropsychological and behavioral development of lead-exposed children after school entry.





Pediatrics. 2004 Jul;114(1):19-26.

Ghio AJ, Piantadosi CA, Crumbliss AL. Hypothesis: iron chelation plays a vital role in neutrophilic inflammation.

Chelation Therapy - Commercial Medical Management Guideline Biometals. 1997;10(2):135-142.

Knudtson ML, Wyse DG, Galbraith PD, et al. Chelation therapy for ischemic heart disease: a randomized controlled trial.

JAMA. 2002;287(4):481-486.

Kolaric K, Bradamante V, Cervek J, et al. A phase II trial of cardioprotection with cardioxane (ICRF-187) in patients with advance breast cancer receiving 5-fluorouracil, doxorubicin and cyclophosphamide. Oncology. 1995;52(3):251-255.

Lin JL, Ho HH, Yu CC. Chelation therapy for patients with elevated body lead burden and progressive renal insufficiency. A randomized, controlled trial. Ann Intern Med. 1999;130(1):7-13.

Lin-Tan DT, Lin JL, Yen TH, Chen KH, Huang YL. Long-term outcome of repeated lead chelation therapy in progressive non-diabetic chronic kidney diseases. Nephrol Dial Transplant. 2007 Oct;22(10):2924-31.

Markowitz ME, Bijur PE, Ruff H, Rosen JF. Effects of calcium disodium versenate (CaNa2EDTA) chelation in moderate childhood lead poisoning. Pediatrics. 1993;92(2):265-271.

O'Connor ME, Rich D. Children with moderately elevated lead levels: is chelation with DMSA helpful? Clin Pediatr (Phila). 1999;38(6):325-331.

Olivieri NF, Brittenham GM, Matsui D, et al. Iron-chelation therapy with oral deferiprone in patients with thalassemia major. N Engl J Med. 1995;332(14):918-922.

Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous beta-thalassemia.

N Engl J Med. 1994;331(9):574-578.

Patel K, Curtis LT. A comprehensive approach to treating autism and attention-deficit hyperactivity disorder: a prepilot study. J Altern Complement Med. 2007 Dec;13(10):1091-7.

Regland B, Lehmann W, Abedini I, et al. Treatment of Alzheimer's disease with clioquinol. Dement Geriatr Cogn Disord.2001;12(6):408-414.

Richardson ME, Matthews RN, Alison JF, et al. Prevention of heart disease by subcutaneous desferrioxamine in patients with thalassemia major. Aust N Z J Med. 1993;23(6):656-661.

Ritchie CW, Bush AI, Mackinnon A, et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Ab amyloid deposition and toxicity in Alzheimer Disease. Arch Neurol. 2003;60(12):1685-1691.

Rogan WJ, Dietrich KN, Ware JH, and Treatment of Lead-Exposed Children Trial Group. The effect of chelation therapy with succimer on neuropsychological development in children exposed to lead. N Engl J Med. 2001;344(19):1421-1426.

Roger SD, Stewart JH, Harris DC. Desferrioxamine enhances the haemopoietic response to erythropoietin, but adverse events are common. Nephron. 1991;58(1):33-36.

Rosen JF, Markowitz ME. Trends in the management of childhood lead poisonings. Neurotoxicology. 1993;14(2-3):211Seely DM, Wu P, Mills EJ. EDTA chelation therapy for cardiovascular disease: a systematic review. BMC Cardiovasc Disord. 2005 Nov 1;5:32.

Chelation Therapy - Commercial Medical Management Guideline

Smart Brief. Web site. 2008. NIH branch drops study of chelation as autism treatment. Available at:

http://www.smartbrief.com/news/FDLI/storyDetails.jsp?issueid=1ACCEA4B-811C-47CA-89FDEA13709B0AE©id=12A3AE3C-5B8D-473E-838B-7743A5262B81. Accessed February 24, 2009.

Snow V, Barry P, Fihn SD, Gibbons RJ, Owens DK, Williams SV, Mottur-Pilson C, Weiss KB; American College of Physicians; American College of Cardiology Chronic Stable Angina Panel. Primary care management of chronic stable angina and asymptomatic suspected or known coronary artery disease: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2004 Oct 5;141(7):562-7. Erratum in: Ann Intern Med. 2005 Jan 4;142(1):79.

Speyer JL, Green MD, Kramer E, et al. Protective effect of the bispiperazinedione ICRF-187 against doxorubicininduced cardiac toxicity in women with advanced breast cancer. N Engl J Med. 1988;319(12):745-752.

Voest EE, Vreugdenhil G, Marx JJM. Iron-chelating agents in non-iron overload conditions. Ann Intern Med.

1994;120(6):490-499.

Vogel J, Bolling S, Costello R, et al. Integrating Complementary Medicine Into Cardiovascular Medicine: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents (Writing Committee to Develop an Expert Consensus Document on Complementary and Integrative Medicine). Journal of the

American College of Cardiology. Vol. 46, No. 1, 2005. Available at:

http://www.acc.org/qualityandscience/clinical/consensus/complementary/index.pdf. Accessed March 13, 2009.

Walshe JM, Yealland M. Chelation treatment of neurological Wilson's disease. Q J Med. 1993;86(3):197-204.

History/Updates Policy update with additional indications added to coverage rationale. HCPCS codes J3490, J3520 and 4/10/2009 diagnosis codes added. Policy 2008T0051E archived.

Policy revision with changes to coverage rationale. CMS information updated. Policy 2007T0051D 12/1/2008 archived.

Policy updated and renamed Chelation Therapy. CMS information updated. Policy 2003T0051C archived.

4/12/2007 HCPCS code S9355 added to Coding Section per direction from the Reimbursement Medical Policy 7/12/2004 Operations Manager.

Medicare entry CIM 35-64 8/21/2003 Policy Updated. Tittle enhanced to include "and Other Indications."

6/19/2003 Policy Reformatted 2/26/2002 Contact Information For questions regarding this policy, send an email to the Medical Technology Interpretation Service at medical_drug_interpretation@uhc.com with the word "Medical" in the subject line.

Coding Chelation Therapy - Commercial Medical Management Guideline The Current Procedural Terminology (CPT) codes and HCPCS codes listed in this policy are for reference purposes only.

Listing of a service code in this policy does not imply that the service described by this code is a covered or non-covered health service. Coverage is determined by the benefit document.

HCPCS Codes:

J0470 Injection, dimercaprol, per 100 mg J0600 Injection, edetate calcium disodium, up to 1000 mg J0895 Injection, deferoxamine mesylate, 500 mg J3490 Unclassified drugs J3520 Edetate disodium, per 150 mg M0300 IV chelation therapy (chemical endarterectomy) S9355 Home infusion therapy, chelation therapy; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem

Diagnosis Codes:

961.1 Poisoning by arsenical anti-infectives 961.2 Poisoning by heavy metal anti-infectives 964.0 Poisoning by iron and its compounds 984.0 Toxic effect of inorganic lead compounds 984.1 Toxic effect of organic lead compounds 984.8 Toxic effect of other lead compounds 984.9 Toxic effect of unspecified lead compound 985.1 Toxic effect of arsenic and its compounds 985.2 Toxic effect of manganese and its compounds 985.3 Toxic effect of beryllium and its compounds 985.4 Toxic effect of antimony and its compounds 985.5 Toxic effect of cadmium and its compounds 985.8 Toxic effect of other specified metals This information is being distributed to you for personal reference. The information belongs to UnitedHealthcare and unauthorized copying, use and distribution are prohibited. This information is intended to serve only as a general reference resource regarding our Medical Policies and is not intended to address every aspect of a clinical situation.

Physicians and patients should not rely on these Medical Policies in making health care decisions. Physicians and patients must exercise their independent clinical discretion and judgment in determining care. The enrollee's specific benefit documents supercede these policies and are used to make coverage determinations. These Medical Policies are believed to be current as of the date noted.

Chelation Therapy - Commercial Medical Management Guideline Confidential and Proprietary, © UnitedHealthcare, Inc. 2009 Chelation Therapy - Commercial Medical Management Guideline TITLE: Cochlear Implants Authorized By: Medical Management Guideline Committee

Adoption Date: 06/29/09 Revision Date:

Disclaimer This medical management guideline represents the recommendation of the PacifiCare Medical Management Guideline (MMG) committee. It is based on the MMG committee's review of the available evidence as of the date of this medical management guideline.

This medical management guideline contains clinical practice and utilization criteria to assist professionals in PacifiCare’s medical management practice when making medical necessity determinations prior to, subsequent to, or concurrent with the provisions of health care services. This medical management guideline is intended to support consistent, appropriate medical necessity determinations, but it does not replace an individualized case-by-case review and medical necessity determination for each PacifiCare member.



Pages:     | 1 |   ...   | 50 | 51 || 53 | 54 |   ...   | 181 |


Similar works:

«COMMUNICABLE DISEASES INFORMATION SHEETS INTRODUCTION The fact sheets presented here summarize communicable diseases that commonly affect students and school staff. They were designed to be used as educational and informational material for students, staff and parents, particularly when outbreaks occur in the school setting. The primary resource for these fact sheets is Red Book: 2003 Report of the Committee on Infectious Diseases, 26th edition, American Academy of Pediatrics. Secondary...»

«Illustrative Cost Models in Learning Disabilities Social Care Provision commissioned by May 2011 healthcare market intelligence ILLUSTRATIVE COST MODELS IN LEARNING DISABILITIES SOCIAL CARE PROVISION Contents Page Introduction Aims and areas of focus 4 Costs, quality and cost-effectiveness 4 Links to other projects and reports 5 Areas not covered and acknowledgements 5 Market shift in types of provision – an introduction 6 Residential Care 6 Supported Living Overview 7 Housing benefits 7...»

«Diane M. Becker, SC.D., M.P.H. THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE CURRENT APPOINTMENTS: Professor, Division of Internal Medicine, The Johns Hopkins University School of Medicine, (primary appointment) Director, Center for Health Promotion Division of Internal Medicine Professor, Health Policy and Management, The Johns Hopkins University, School of Public Health, (joint appointment) Adjunct Professor, Medicine, Brown University School of Medicine, Providence, RI PERSONAL: The Johns...»

«A Nutrition Guide for Women with Breast Cancer Revised Fall 2012 Acknowledgements Appreciation is expressed to the women from across Canada who participated in interviews and focus groups to plan and field-test this booklet. From the start, it was their questions and ideas that shaped the booklet. Developed by: BC Cancer Agency www.bccancer.bc.ca HealthLink BC www.HealthLinkBC.ca This publication was created with the support of the Canadian Cancer Society, BC and Yukon Division. This revision...»

«1111 Competency-Based Human Resource Development Strategy Noordeen T. Gangani Gary N. McLean University of Minnesota Richard A. Braden West Group This paper explores issues in developing and implementing a competency-based human resource development strategy. The paper summarizes a literature review on how competency models can improve HR performance. A case study is presented of American Medical Systems (AMS), a mid-sized health-care and medical device company, where the model is being used to...»

«Development of carbamate modified PEI for delivery of a granzyme B inhibitor gene to protect against cytotoxic lymphocyte killing Wei Cheng Imperial College London Section of Immunobiology, Division of Immunology and Inflammation, Department of Medicine, Faculty of Medicine Thesis submitted for the degree of PhD DECLARATION OF ORIGINALITY This is to certify that to the best of my knowledge, the work presented in this thesis is my own, and it has not been previously submitted for a degree or...»

«Swedish University of Agricultural Sciences Faculty of Veterinary Medicine and Animal Science Transcriptome Analysis of Atlantic Herring (Clupea harengus) using Next Generation Sequencing (NGS)) Nima Rafati Examensarbete / Swedish University of Agricultural Sciences, Master’s Thesis, 30 HEC Department of Animal Breeding and Genetics, Erasmus Mundus Programme 405 – European Master in Animal Breeding and Genetics Uppsala 2013 Swedish University of Agricultural Sciences Faculty of Veterinary...»

«[Cite as Akin v. Akin, 2011-Ohio-2765.] STATE OF OHIO ) IN THE COURT OF APPEALS )ss: NINTH JUDICIAL DISTRICT COUNTY OF SUMMIT ) JASON A. AKIN C.A. Nos. 25524 Appellee/Cross-Appellant v. APPEAL FROM JUDGMENT CHRISTINA M. AKIN ENTERED IN THE COURT OF COMMON PLEAS Appellant/Cross-Appellee COUNTY OF SUMMIT, OHIO CASE No. 2007-06-2013 DECISION AND JOURNAL ENTRY Dated: June 8, 2011 DICKINSON, Judge. INTRODUCTION {1} Jason and Christina Akin divorced in Texas in 2000. They have two daughters. In 2007,...»

«! 
 ! Show Standards for Rats
 Version 3.0
 
 General • All animals brought to the show, whether being entered or not, should be of good health, in excellent condition and free from parasites. Please refer to the Rat Entry Conditions for further details regarding expectations of animals brought to club events. 
 !• Enclosures brought along to house rodents on the day of a club event are to be clean with fresh bedding and be supplied with adequate food and water. Heavily soiled,...»

«Exploiting spatial and temporal variation in nutrition at birth, using data on infant mortality and famines: a study of long-run health effects Mevlude Akbulut-Yuksel1, Gerard J. van den Berg2, and Katharina Walliczek3 Dalhousie University, IZA and HICN University of Mannheim, IFAU-Uppsala, VU University Amsterdam and IZA University of Mannheim Very Preliminary Not For Citation February 2013 Abstract We study long-run health effects of nutritional conditions early in life exploiting spatial...»

«Reaching out through the web MILAN BREAST CANCER CONFERENCE t Webcast and residential en em nc ou 23/26 June 2015 nn da 2n Innovation in care and Chair: Umberto Veronesi research Aron Goldhirsch Mario Rietjens Scientific Committee: ww Saverio Cinieri w.b Marco Colleoni rea Giuseppe Curigliano stm Francesca De Lorenzi ila Viviana Galimberti n.c Mattia Intra om Offering health care professionals who care for breast cancer patients access to the most advanced developments in patient care and...»

«The impact of intragenic CpG content on epigenetic control of transgene expression in mammalian cells DISSERTATION ZUR ERLANGUNG DES DOKTORGRADES DER NATURWISSENSCHAFTEN (DR. RER. NAT.) DER FAKULTÄT FÜR BIOLOGIE UND VORKLINISCHE MEDIZIN DER UNIVERSITÄT REGENSBURG vorgelegt von Simone Krinner aus Straubing im Jahr 2012 Das Promotionsgesuch wurde eingereicht am 6. November 2012 Die Arbeit wurde angeleitet von Prof. Dr. Ralf Wagner Simone Krinner Prüfungsausschuss: Vorsitz: Prof. Dr. Stephan...»





 
<<  HOME   |    CONTACTS
2016 www.thesis.xlibx.info - Thesis, documentation, books

Materials of this site are available for review, all rights belong to their respective owners.
If you do not agree with the fact that your material is placed on this site, please, email us, we will within 1-2 business days delete him.